Navigation Links
Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013
Date:5/28/2009

Positive clinical data, competitor focus, and new drug-eluting technologies to drive lower extremity procedures in Europe, according to Millennium Research Group

WALTHAM, Mass., May 28 /PRNewswire/ -- According to Millennium Research Group's (MRG's) European Markets for Peripheral Vascular (PV) Devices 2009 report, rapid growth in the number of endovascular procedures that treat lower extremity peripheral artery disease in Europe is being fueled by positive clinical trial results, increased competitor focus, and the release of new drug-eluting devices for these indications. Combined, these factors will drive the markets for lower extremity PV stents and percutaneous transluminal angioplasty (PTA) balloon catheters to reach combined revenues in excess of $180 million by 2013.

The number of endovascular femoropopliteal (fem-pop) procedures performed in Europe is experiencing double-digit year-over-year growth, driven primarily by positive data released from clinical trials such as Cordis' SIROCCO and Edwards Lifesciences' RESILIENT. The positive results from these trials have demonstrated both promising patency rates and reduced stent fracture rates, which will continue to bolster physician confidence in fem-pop stenting. Fem-pop PTA procedure volumes in Europe will grow in tandem with fem-pop stenting, which often involves predilation of the lesion or postdilation of the stent using PTA balloon catheters. As a result, most major PV stent manufacturers are now focusing on the fem-pop indication for technology development and marketing.

"Endovascular infrapopliteal procedures, which treat below-the-knee peripheral artery disease, are also growing rapidly," says Stephanie Labelle, Senior Analyst at MRG. "Although revenues in both the PV stent and PTA balloon catheter markets were relatively small for the infrapopliteal indication in 2008, infrapopliteal procedures will continue to outgrow other PV stenting indications through 2013. In addition, the introduction of drug-eluting stents and balloons indicated for infrapopliteal procedures will generate a considerable amount of physician excitement, which will help to boost market revenues over the years to come."

MRG's European Markets for Peripheral Vascular Devices 2009 report provides coverage of key industry competitors, including Abbott Vascular, Boston Scientific, Cook Medical, Cordis, C. R. Bard, Medtronic Vascular, Terumo Medical, W. L. Gore, and many more.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through syndicated reports, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources, Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms
2. AHRQ-Funded Study Finds Lower Risk of Death and Heart Attack in Patients With Drug-Coated Stent Implants Compared to Those With Bare Metal Stents
3. New Study Suggests Cholesterol-Lowering Statins Reduce Severe Asthma Attacks that Result in Hospitalizations and Emergency Room Visits
4. Experience Not Always the Best Prescription for Snowblowers
5. Statins Lower Stroke Severity, Improve Recovery
6. Risk of Stroke, Heart Disease in Women Lowered by Mediterranean Diet
7. AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly
8. Implantable Defibrillators Lower Risk of Death in Older Heart Patients
9. Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
10. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
11. Want a Reason to Love Your Lower Belly Fat? Its Rich in Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work ... as “patient engagement.” The patient is doing more than filling out a survey; in ... “There is an increasing emphasis in health care and research on the importance of ...
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
Breaking Medicine News(10 mins):